Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
about
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer modelRecent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtypeThe epidemiology of triple-negative breast cancer, including raceCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesTriple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-AnalysisDecoding the usefulness of non-coding RNAs as breast cancer markersThe combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors"Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen responseRb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues.Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.Model-based clustering of array CGH data.Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft modelsDysregulated miR-183 inhibits migration in breast cancer cells.Hypothesized role of pregnancy hormones on HER2+ breast tumor development.The prediction models for postoperative overall survival and disease-free survival in patients with breast cancerWhat does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?Molecular insights on basal-like breast cancer.Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study.Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrenceReproductive history and risk of three breast cancer subtypes defined by three biomarkers.Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort.Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtypeIntegrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer.Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses.Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform.Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer.Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.
P2860
Q21090788-728BE320-356F-403A-8CF1-FF3695CAB509Q21195226-0458A38C-6D7E-4AED-8ABF-846B1C6DA70BQ24289471-D39DCECB-F39E-4697-A983-43C018EC828FQ26743510-6A55CD6B-E034-4679-99E6-700FD858C135Q26753881-1F770AD1-D198-416D-A657-D8D8EBF1A624Q28069370-ABDAE524-0438-4150-AFC6-35AEC238AA16Q28279114-C4B3E914-1AD4-44B6-BB8A-314F31444DDDQ28751755-867B9969-6AA0-409E-BBFB-987DA4E28D77Q30496322-1EF3CCEC-50A2-4967-BC62-0F28C89E52BFQ33328683-294C7552-6B7B-4507-B82C-90EDBFB302ADQ33333952-1803D6D7-357F-448A-9E62-C5D826C7D7BEQ33455313-F72969A5-CB14-4D0D-B58E-8F5E582EA61AQ33500786-71790404-43CC-492C-8330-E75729A661ABQ33575459-4AF2DCE5-11FF-42B6-A030-D4B1B14B9B97Q33660965-72C498D1-6621-4B7A-A155-CBD74C054DF1Q33698660-9341F9F6-0708-43A2-8AC9-5DBE1F3CFDF4Q33745434-742F5A47-E2DB-4050-B9CD-E9506BA377FAQ33891155-C9D63B56-2275-4B7E-A46D-FD557737C9ADQ33990937-616A2728-4EC6-41D8-B6B3-7B5FF3AA157BQ34123314-489721AB-C31C-406B-821F-6855A0A17A72Q34303319-29BF33B5-A8A6-44F8-9FEC-DFC06E33B650Q34376320-2FF90B35-A822-499A-9802-4014BA8FC728Q34378272-76B3D033-396B-487A-A2FA-1C1980009B09Q34584855-BE92D8FA-4F9C-467B-B667-D34E809C599BQ34590295-0C401B38-8EA1-4837-AC63-E5FE42AFCF7BQ34977042-17357ECC-97D9-4C93-B4D7-0C8F52ED604AQ34979662-7BCA55DD-185A-4A55-B577-B922EA2AA119Q35029548-E6AA9861-8431-4FB7-8FE0-A9C770BEB28DQ35050475-9071E776-C03F-4467-A646-A3F440D07EACQ35125648-8DEB880E-BB96-4BE5-806B-7FBEAE36E586Q35142129-0C69D0E0-DADA-4751-8FF8-AA45B8E897E2Q35561695-CA7F918A-AD3E-4EFA-B9CB-810377456367Q35589239-02F64C39-7BB2-4E39-980C-0356F2AE1333Q35605761-90EC8A04-F28E-44C7-BE45-0652CDD08759Q35623047-B6598770-E929-4AD7-BB75-7BA1F887789BQ35662191-ABAE4093-21EF-4A96-B130-29D0470CE6ACQ35694329-D554ED3D-4BDF-4607-A135-174CA27E51C8Q35872691-17E3E6C8-B3EA-42ED-839E-8AB820454E07Q35918620-DB44F660-4793-49B2-AFEC-E3950F0E1FE0Q35941288-CD7FB201-C773-460B-A63A-8AC2BB9E9041
P2860
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@ast
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@en
type
label
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@ast
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@en
prefLabel
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@ast
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@en
P1476
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
@en
P304
P356
10.1016/J.EJCA.2004.08.021
P577
2004-12-01T00:00:00Z